[go: up one dir, main page]

WO2011100282A2 - Polymorphes de mésylate d'imatinib - Google Patents

Polymorphes de mésylate d'imatinib Download PDF

Info

Publication number
WO2011100282A2
WO2011100282A2 PCT/US2011/024137 US2011024137W WO2011100282A2 WO 2011100282 A2 WO2011100282 A2 WO 2011100282A2 US 2011024137 W US2011024137 W US 2011024137W WO 2011100282 A2 WO2011100282 A2 WO 2011100282A2
Authority
WO
WIPO (PCT)
Prior art keywords
imatinib mesylate
crystalline form
imatinib
solution
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/024137
Other languages
English (en)
Other versions
WO2011100282A3 (fr
Inventor
Vamsi Krishna Mudapaka
Sesha Reddy Yarraguntla
Venu Nalivela
Vamsee Krishna Muppidi
Rajesham Boge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Inc
Original Assignee
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd, Dr Reddys Laboratories Inc filed Critical Dr Reddys Laboratories Ltd
Publication of WO2011100282A2 publication Critical patent/WO2011100282A2/fr
Publication of WO2011100282A3 publication Critical patent/WO2011100282A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • aspects of the present application relate to crystalline forms of imatinib mesylate and process for preparation thereof. Further aspects relate to the use of the crystalline forms in the preparation of pharmaceutical compositions.
  • the drug compound having the adopted name "imatinib mesylate” has a chemical name 4-[(4-methyl-1 -piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)- 2-pyrimidinyl]amino]-phenyl]benzamide methanesulfonate and is structurally represented by Formula I.
  • Imatinib is a protein tyrosine kinase inhibitor available in products sold using the trademark GLEEVECTM, in the form of tablets containing imatinib mesylate equivalent to 100 mg or 400 mg of imatinib free base.
  • Zimmermann et al. in U.S. Patent No. 6,894,051 , describe two crystalline forms of imatinib mesylate, the alpha-form and the beta-form.
  • Zimmermann et al. in U.S. Patent No. 7,544,799, describe a crystalline form of a methanesulfonic acid addition salt of imatinib having non-needle shaped crystals, and its pharmaceutical composition.
  • Parthasaradhi et al. in U.S. Patent No. 7,300,938, describe crystalline imatinib mesylate Form H1 , imatinib mesylate hydrate, amorphous imatinib mesylate hydrate, and processes for the preparation thereof.
  • International Application Publication No. WO 2005/077933 A1 describes an alpha 2-crystalline form of imatinib mesylate and a process for the preparation of the imatinib mesylate polymorphic form.
  • International Application Publication No. WO 2006/054314 A1 describes crystalline Form-I and Form-ll of imatinib mesylate, and processes for preparation thereof.
  • International Application Publication No. WO 2006/048890 A1 describes a non-needle shaped alpha- crystalline form of imatinib mesylate and a process for its preparation.
  • International Application Publication No. WO 2007/136510 A2 describes crystalline imatinib mesylate, wherein the crystalline form is a solvate.
  • this application describes crystalline imatinib mesylate Forms IV (ethanol solvate), V, VI (1 ,3-dioxalane solvate), VII (nitromethane solvate), VIII (2-propanol solvate), IX, X (ethanol solvate), XI, XIII, XIV (2-propanol solvate), XV (mono-solvate of acetic acid), XVI (hemi-solvate of acetic acid), an amorphous form, and a process for preparing crystalline imatinib mesylate Form-alpha.
  • WO 2007/023182 A1 describes crystalline forms delta and epsilon of imatinib mesylate and processes for the preparation thereof.
  • International Application Publication No. WO 2007/059963 A1 describes crystalline forms F, G, H, I, and K of imatinib mesylate and processes for the preparation thereof.
  • International Application Publication No. WO 2008/027600 A2 describes a solid solution comprising imatinib and a solid solvent, and its process.
  • International Application Publication No. WO 2008/1 12722 A2 describes a solid dispersion of imatinib mesylate comprising imatinib mesylate and a pharmaceutically acceptable carrier, wherein the carrier is a cellulose derivative.
  • International Application Publication No. WO2008/150481 A2 describes a method of preparing crystalline imatinib mesylate form beta, from crystalline imatinib mesylate Form IV.
  • Adin ef a/. in U.S. Patent Application Publication No. 2006/0223816 A1 , describe a stable, free-flowing imatinib mesylate alpha-form, which is substantially free of the beta-form.
  • Pathi ef a/. in U.S. Patent Application Publication No. 2007/0265288 A1 , describe a method of preparing crystalline imatinib mesylate alpha-form, involving the use of an alcohol or ketone solvent.
  • Szczepek ef a/. in U.S. Patent Application Publication No. 2007/0197545 A1 , describe a process for the preparation of alpha-crystal form of imatinib mesylate.
  • Weisman et al. in U.S. Patent Application Publication No. 2008/0234286 A1 , describes a stable micronized amorphous form, having a water content in the range of 3.2-5%.
  • Indian Patent Application No. 1208/MUM/2003 describes a substantially amorphous form of imatinib mesylate and a process for preparation thereof.
  • Indian Patent Application No. 209/MUM/2003 describes a gamma form of imatinib mesylate, comprising imatinib mesylate in a stable, substantially amorphous form comprising about 1.5 to 5% w/w water and a process for the preparation thereof.
  • aspects of the present application relate to crystalline forms of imatinib mesylate designated as Form-Y, Form-Y', Form-Z, and processes for preparation thereof.
  • Form-Y a crystalline form of imatinib mesylate, which is designated herein as "Form-Y.”
  • Form-Y may be characterized using one or more analytical methods.
  • a crystalline Form-Y of imatinib mesylate characterized by an X-ray powder diffraction (XRPD) pattern substantially as shown in Figure 1 , Figure 4, or Figure 5.
  • XRPD X-ray powder diffraction
  • a crystalline Form-Y of imatinib mesylate characterized by an X-ray powder diffraction (XRPD) pattern comprising two or more of the characteristic peaks located at about 6.1 , 8.7, 1 1.5, 14.5, 18.0,
  • the present application provides a process for the preparation of crystalline Form-Y of imatinib mesylate, comprising:
  • step b) adding an ether solvent to the solution of step a);
  • Form-Y 1 a crystalline form of imatinib mesylate, which is designated herein as "Form-Y 1 .”
  • Form-Y' may be characterized using one or more analytical methods.
  • a crystalline Form-Y' of imatinib mesylate characterized by an X-ray powder diffraction (XRPD) pattern substantially as shown in Figure 8 or Figure 9.
  • the present application provides a process for the preparation of crystalline Form-Y' of imatinib mesylate, comprising:
  • the present invention provides a crystalline form of imatinib mesylate, which is designated herein as "Form-Z.”
  • Form-Z may be characterized using one or more analytical methods.
  • a crystalline Form-Z of imatinib mesylate characterized by an X-ray powder diffraction (XRPD) pattern substantially as shown in Figure 10.
  • a crystalline Form-Z of imatinib mesylate characterized by an X-ray powder diffraction (XRPD) pattern comprising two or more of the characteristic peaks located at about 6.6, 8.0, 13.9, 16.6, 17.0, 17.3, 18.4, 19.0, 20.2, 22.2, or 24.2 ⁇ 0.2 degrees 2-theta.
  • XRPD X-ray powder diffraction
  • the present application provides a process for the preparation of crystalline Form-Z of imatinib mesylate, comprising:
  • step b) combining the solution of step a) with a halogenated hydrocarbon solvent;
  • crystalline Form-Z of imatinib mesylate optionally, drying the solid to afford crystalline Form-Z of imatinib mesylate.
  • the crystalline Form-Y, Form-Y', and Form-Z of imatinib mesylate produced according to the processes of the present application are sufficiently stable for commercial purposes and useful for making pharmaceutical dosage forms for the treatment of diseases, including, but not limited to, Philadelphia positive chronic myeloid leukemia.
  • the present application provides a pharmaceutical formulation comprising crystalline Form-Y of imatinib mesylate and at least one pharmaceutically acceptable excipient.
  • the present application provides a pharmaceutical formulation comprising crystalline Form-Y' of imatinib mesylate and at least one pharmaceutically acceptable excipient.
  • the present application provides a pharmaceutical formulation comprising crystalline Form-Z of imatinib mesylate and at least one pharmaceutically acceptable excipient.
  • Figure 1 is an illustrative example of an X-ray powder diffraction pattern of crystalline Form-Y of imatinib mesylate, prepared according to Example 1.
  • FIG. 2 is an illustrative example of a differential scanning calorimetry ("DSC") curve of crystalline Form-Y of imatinib mesylate, prepared according to Example 1.
  • DSC differential scanning calorimetry
  • FIG 3 is an illustrative example of a thermogravimetric analysis (“TGA”) curve of crystalline Form-Y of imatinib mesylate, prepared according to Example 1.
  • TGA thermogravimetric analysis
  • Figure 4 is an illustrative example of an X-ray powder diffraction pattern of crystalline Form-Y of imatinib mesylate, prepared according to Example 1 (Sample - 1).
  • Figure 5 is an illustrative example of an X-ray powder diffraction pattern of crystalline Form-Y of imatinib mesylate, prepared according to Example 2.
  • Figure 6 is an illustrative example of a DSC curve of crystalline Form-Y of imatinib mesylate, prepared according to Example 2.
  • Figure 7 is an illustrative example of a TGA curve of crystalline Form-Y of imatinib mesylate, prepared according to Example 2.
  • Figure 8 is an illustrative example of an X-ray powder diffraction pattern of crystalline Form-Y' of imatinib mesylate, prepared according to Example 3.
  • Figure 9 is an illustrative example of an X-ray powder diffraction pattern of crystalline Form-Y' of imatinib mesylate prepared according to Example 4.
  • Figure 10 is an illustrative example of an X-ray powder diffraction pattern of crystalline Form-Z of imatinib mesylate, prepared according to Example 5.
  • aspects of the present application relate to crystalline forms of imatinib mesylate designated as Form-Y, Form-Y', Form-Z, and processes for preparation thereof.
  • Crystalline forms Form-Y, Form-Y', and Form-Z of imatinib mesylate may be characterized by any one or more analytical results which may include X-ray powder diffraction ("XRPD”) patterns, differential scanning calorimetry (“DSC”) curves, and thermogravimetric analysis (“TGA”) curves.
  • XRPD X-ray powder diffraction
  • DSC differential scanning calorimetry
  • TGA thermogravimetric analysis
  • Form-Y a crystalline form of imatinib mesylate, which is designated herein as "Form-Y.”
  • Form-Y may be characterized using one or more analytical methods.
  • a crystalline Form-Y of imatinib mesylate characterized by an X-ray powder diffraction (XRPD) pattern substantially as shown in Figure 1 , Figure 4, or Figure 5.
  • XRPD X-ray powder diffraction
  • a crystalline Form-Y of imatinib mesylate characterized by an X-ray powder diffraction (XRPD) pattern comprising two or more of the characteristic peaks located at about 6.1 , 8.7, 1 1.5, 14.5, 18.0, 18.7, 20.1 , 21.9, or 22.5 ⁇ 0.2 degrees 2-theta.
  • XRPD X-ray powder diffraction
  • Crystalline Form-Y of imatinib mesylate may be characterized using one or more of the following analytical methods: its XRPD pattern, substantially in accordance with Figure 1 , Figure 4, or Figure 5; its DSC curve, substantially in accordance with Figure 2 or Figure 6; and its TGA curve, substantially in accordance with Figure 3 or Figure 7.
  • a crystalline Form-Y of imatinib mesylate characterized by XRPD pattern, substantially in accordance with Figure 1.
  • a crystalline Form Y of imatinib mesylate characterized by its DSC curve, substantially in accordance with Figure 2.
  • the present application provides a process for the preparation of crystalline Form-Y of imatinib mesylate, comprising:
  • step b) adding an ether solvent to the solution of step a);
  • Step a) includes providing a solution of imatinib and methanesulfonic acid in methanol.
  • the solution of imatinib and methanesulfonic acid may be obtained by the combining imatinib with the solvent, followed by the addition of methanesulfonic acid.
  • Any form of imatinib is acceptable for forming a solution, such as a crystalline or amorphous form.
  • the quantity of methanol used for providing a solution may range from about 5 mL to about 15 mL, or about 10 mL, per gram of imatinib base.
  • the solution may be prepared at any temperatures up to the boiling point of the solvent, e.g., from about -10°C to about reflux temperature of methanol.
  • the solution may be prepared at lower temperatures, such as below 20°C, or in the range of about -5°C to about 0°C.
  • the solution may be optionally treated with activated charcoal or sodium sulfate, and then filtered to remove the carbon or sodium sulfate.
  • the solution may optionally be filtered by passing through paper, glass fiber, or other membrane material, or a bed of a clarifying agent such as Celite®.
  • the filtration apparatus may need to be heated or cooled to avoid undesired crystallization.
  • Step b) includes adding ether as an anti-solvent to a solution of a).
  • Anti- solvents that may be used for the preparation of imatinib mesylate Form-Y include, but are not limited to, ethers such as diethyl ether, diisopropyl ether, methyl tertiary- butyl ether (MTBE), or the like.
  • the quantities of anti-solvent used may range from about 10 mL to about 45 mL, or about 40 mL, per gram of imatinib base.
  • the addition of anti-solvent may be performed at any temperatures, including about -10°C to about 30°C.
  • the obtained suspension may be stirred for about 15 minutes to about 2 hours, or longer, to enhance the extent of crystallization.
  • Useful temperatures for maintaining a suspension may range from about -5°C to about 35°C.
  • Step c) includes isolating a solid from the mixture of step b).
  • the solid may be isolated from the suspension using general techniques known to persons skilled in the art for separating solids from liquids.
  • the solid may be isolated by using techniques such as, for example, filtration by gravity or by suction, centrifugation, decantation, or the like.
  • the solid may optionally be washed with a suitable solvent such as diethyl ether, diisopropyl ether, MTBE, or the like.
  • Step d) includes drying the solid to afford crystalline Form-Y of imatinib mesylate.
  • the obtained solid of imatinib mesylate may be dried.
  • the drying of solid material may be carried out under suitable conditions to afford the desired crystalline form of imatinib mesylate, substantially free of residual solvents. Drying may be carried out at reduced pressures, such as more than about 500 mm Hg, at temperatures such as about 35°C to about 60°C or higher, or about 45°C. Drying may be suitably carried out in equipment such as a rotary dryer, tray dryer, vacuum oven, air oven, humidity dryer, fluidized bed dryer, spin flash dryer, flash dryer, or combinations thereof.
  • the drying of solid can be carried out in a controlled humidity environment having a relative humidity ("RH"), such as below 75% RH or between about 30 to 75% RH, at temperatures such as about 20- 50°C. Exposure to an environment containing relative humidity can reduce the residual solvent content.
  • the humidification drying may be performed for any desired time periods that achieve the desired product purity and residual solvent content, such as times from about 1 hour to about 30 hours, or longer. Drying may also be carried out for shorter or longer periods of time depending on the product specifications.
  • the product obtained from the humidity drying may be further dried using any of the suitable drying techniques mentioned above, especially to remove the water content.
  • the said drying may be carried out in three stages, the first being drying under reduced pressure in a tray dryer, the second being drying under controlled humidity environment and third step being drying under reduced pressure in a tray dryer.
  • the crystalline Form-Y of Imatinib mesylate obtained by the process of the present application may have a polymorphic purity of greater than about 95%, or greater than about 98%, or greater than about 98.5%, or greater than about 99.0%, or greater than about 99.5%.
  • the crystalline Form-Y of imatinib mesylate obtained by the process of the present application may be utilized for the preparation of amorphous as well as other crystalline polymorphs.
  • the present application provides pharmaceutical formulations comprising crystalline Form-Y of imatinib mesylate and at least one pharmaceutically acceptable excipient.
  • Crystalline Form-Y of imatinib mesylate produced according to a process of the present invention is sufficiently stable for commercial purposes. Crystalline Form-Y is useful for making pharmaceutical dosage forms for the treatment of diseases, including, but not limited to, Philadelphia positive chronic myeloid leukemia.
  • Form-Y 1 a crystalline form of imatinib mesylate, which is designated herein as "Form-Y 1 .”
  • Form-Y' may be characterized using one or more analytical methods.
  • the crystalline Form-Y' of imatinib mesylate characterized by an X-ray powder diffraction pattern having peak reflections at about 6.1 , 8.7, 1 1.5, 14.5, 18.0, 18.7, 20.1 , 21.9, or 22.5 ⁇ 0.2 degrees 2-theta obtained by the process of present application may be represented by an X-ray powder diffraction substantially as described in Figure 8 or Figure 9.
  • the present application provides a process for the preparation of crystalline Form-Y' of imatinib mesylate, comprising:
  • Step a) includes providing a solution of imatinib and methanesulfonic acid in methanol.
  • the solution of imatinib and methanesulfonic acid may be obtained by the combining imatinib with the solvent, followed by the addition of methanesulfonic acid.
  • Any form of imatinib is acceptable for forming a solution, such as a crystalline or amorphous form.
  • the quantity of methanol used for providing a solution may range from about 5 ml_ to about 15 ml_, or about 10 mL, per gram of imatinib base.
  • the solution may be prepared at any temperatures up to the boiling point of the solvent, e.g., from about -10°C to about reflux temperature of methanol.
  • the solution may be prepared at lower temperatures, such as below 20°C, or in the range of about -5°C to about 0°C.
  • the solution may be optionally treated with activated charcoal or sodium sulfate, and then filtered to remove the carbon or sodium sulfate.
  • the solution may optionally be filtered by passing through paper, glass fiber, or other membrane material, or a bed of a clarifying agent such as Celite®.
  • the filtration apparatus may need to be heated or cooled to avoid undesired crystallization.
  • Step b) includes optionally adding a seed material
  • seed material may optionally be added to the solution of step a).
  • Seed material that may be used in step b) may be the crystalline Form-Y or crystalline Form-Y of imatinib mesylate.
  • the seed material of crystalline Form-Y or crystalline Form-Y' of imatinib mesylate may be prepared by a process as described in the present application.
  • Step c) includes adding an ether solvent.
  • the ether solvent may be added to the solution of step a) or to that of step b) depending on the seeding operation.
  • the ether solvent is added to an admixture of step b).
  • the ether solvent that may be used as anti-solvents for the preparation of imatinib mesylate Form-Y include, but are not limited to, diethyl ether, diisopropyl ether, methyl tertiary- butyl ether (MTBE), or the like.
  • the quantities of anti-solvent used may range from about 10 mL to about 45 mL, or about 40 mL, per gram of imatinib base.
  • anti-solvent may be performed at any temperatures, including about -10°C to about 30°C.
  • the obtained suspension may be stirred for about 15 minutes to about 2 hours, or longer, to enhance the extent of crystallization.
  • Useful temperatures for maintaining a suspension may range from about -5°C to about 35°C.
  • Step d) includes isolating a solid from the mixture of step b).
  • the solid may be isolated from the suspension using general techniques known to persons skilled in the art for separating solids from liquids.
  • the solid may be isolated by using techniques such as, for example, filtration by gravity or by suction, centrifugation, decantation, or the like.
  • the solid may optionally be washed with a suitable solvent such as diethyl ether, diisopropyl ether, MTBE, or the like.
  • Step e) includes drying the solid to afford crystalline Form-Y' of imatinib mesylate.
  • the obtained solid of imatinib mesylate may be dried.
  • the drying of solid material may be carried out under suitable conditions to afford the desired crystalline form of imatinib mesylate, substantially free of residual solvents. Drying may be carried out at reduced pressures, such as more than about 500 mm Hg, at temperatures such as about 35°C to about 60°C or higher, or about 45°C. Drying may be suitably carried out in equipment such as a rotary dryer, tray dryer, vacuum oven, air oven, humidity dryer, fluidized bed dryer, spin flash dryer, flash dryer, or combinations thereof.
  • the drying of solid can be carried out in a controlled humidity environment having a relative humidity ("RH"), such as below 75% RH or between about 30 to 75% RH, at temperatures such as about 20- 50°C. Exposure to an environment containing relative humidity can reduce the residual solvent content.
  • the humidification drying may be performed for any desired time periods that achieve the desired product purity and residual solvent content, such as times from about 1 hour to about 30 hours, or longer. Drying may also be carried out for shorter or longer periods of time depending on the product specifications.
  • the product obtained from the humidity drying may be further dried using any of the suitable drying techniques mentioned above, especially to remove the water content.
  • the said drying may be carried out in three stages, the first being drying under reduced pressure in a tray dryer, the second being drying under controlled humidity environment and third step being drying under reduced pressure in a tray dryer.
  • the crystalline Form-Y' of Imatinib mesylate obtained by the process of the present application may have a polymorphic purity of greater than about 95%, or greater than about 98%, or greater than about 98.5%, or greater than about 99.0%, or greater than about 99.5%.
  • the crystalline Form-Y' of imatinib mesylate obtained by the process of the present application may be utilized for the preparation of amorphous as well as other crystalline polymorphs.
  • the present application provides pharmaceutical formulations comprising crystalline Form-Y' of imatinib mesylate and at least one pharmaceutically acceptable excipient.
  • Crystalline Form-Y' of imatinib mesylate produced according to a process of the present invention is sufficiently stable for commercial purposes. Crystalline Form-Y' is useful for making pharmaceutical dosage forms for the treatment of diseases, including, but not limited to, Philadelphia positive chronic myeloid leukemia.
  • the present invention provides a crystalline form of imatinib mesylate, which is designated herein as "Form-Z.”
  • Form-Z may be characterized using one or more analytical methods.
  • a crystalline Form-Z of imatinib mesylate characterized by an X-ray powder diffraction (XRPD) pattern substantially as shown in Figure 10.
  • a crystalline Form-Z of imatinib mesylate characterized by an X-ray powder diffraction (XRPD) pattern comprising two or more of the characteristic peaks located at about 6.6, 8.0, 13.9, 16.6, 17.0, 17.3, 18.4, 19.0, 20.2, 22.2, or 24.2 ⁇ 0.2 degrees 2-theta.
  • XRPD X-ray powder diffraction
  • the present application provides a process for the preparation of crystalline Form-Z of imatinib mesylate, comprising:
  • step a) a) providing a solution of imatinib mesylate in dimethylsulphoxide; b) combining the solution of step a) with a halogenated hydrocarbon solvent;
  • Step a) includes providing a solution of imatinib mesylate in dimethylsulfoxide.
  • the solution of imatinib mesylate may be obtained by the combining imatinib mesylate with dimethylsulfoxide or it may be obtained from a reaction step in which the compound is prepared. Any form of imatinib mesylate is acceptable for forming a solution, such as a crystalline or amorphous form.
  • the quantity of dimethylsulfoxide used for providing a solution may range from about 2 ml_ to about 20 ml_, or more, per gram of imatinib mesylate.
  • the solution may be prepared at any temperatures up to the boiling point, e.g., from about 0°C to about reflux temperature of dimethylsulfoxide. In embodiments, the solution may be prepared at temperatures from about 60°C to about 95°C.
  • the solution may optionally be treated with activated charcoal and then filtered to remove the carbon.
  • the solution may optionally be filtered by passing through paper, glass fiber, or other membrane material, or a bed of a clarifying agent such as Celite®.
  • the filtration apparatus may need to be heated or cooled to avoid undesired crystallization.
  • Step b) includes combining the solution of step a) with a halogenated hydrocarbon solvent.
  • Halogenated hydrocarbon solvents such as dichloromethane or chloroform may be used as an anti-solvent for crystallizing the material from the solution of step a).
  • Any other suitable solvents other than halogenated hydrocarbon solvents that can crystallizes the material from the solution of step a) may also be used as an anti-solvent as long as it provides Form Z of the present application
  • the quantities of anti-solvent used may range from about 20 mL to about 60 ml_, or about 50 mL, per gram of imatinib mesylate.
  • the solution of step a) is added to the anti-solvent.
  • the addition may be performed at temperatures ranging from about - 10°C to about 25°C.
  • the solution of step a) is added to anti-solvent, e.g., dichloromethane, precooled to temperatures in the range from about 0°C to about -5°C.
  • the mixture obtained may be stirred for a time from about 15 minutes to about 3 hours, or longer, within the same temperature range to enhance the extent of crystallization.
  • Step c) includes isolating the solid obtained.
  • the solid may be isolated from the suspension using general techniques known to persons skilled in the art for separating solids from liquids.
  • the solid may be isolated by using techniques such as, for example, filtration by gravity or by suction, centrifugation, decantation, or the like. After isolation, the solid may optionally be washed with the anti-solvent used in step b).
  • Step d) includes optionally drying the solid, to afford crystalline Form-Z of imatinib mesylate.
  • the drying of solid material may be carried out under suitable conditions to afford the desired crystalline form of imatinib mesylate, substantially free of residual solvents. Drying may be carried out at reduced pressures, such as more than about 500 mm Hg, at temperatures from about 50°C to about 70°C, or about 60°C.
  • the crystalline Form-Z of Imatinib mesylate obtained by the process of the present application may have a polymorphic purity of greater than about 95%, or greater than about 98%, or greater than about 98.5%, or greater than about 99.0%, or greater than about 99.5%.
  • the crystalline Form-Z of imatinib mesylate obtained from the present application may be utilized for the preparation of amorphous as well as other crystalline polymorphs.
  • the present application provides pharmaceutical formulations comprising crystalline Form-Z of imatinib mesylate, together with at least one pharmaceutically acceptable excipient.
  • polymorphs The occurrence of different polymorphs is possible for some compounds.
  • a single compound may give rise to a variety of solids having distinct physical properties, such as X-ray diffraction patterns, infrared absorption spectra, and NMR spectra. This variation in solid forms may be significant and may result in differences with respect to bioavailability, stability, and other differences for formulated pharmaceutical products.
  • polymorphic forms can vary in their physical properties, regulatory authorities require that efforts shall be made to identify all polymorphic forms, e.g., crystalline, amorphous, solvated, etc., of new drug substances.
  • polymorphic forms for a given compound cannot be predicted, and there are no "standard" procedures that can be used to prepare polymorphic forms of a substance.
  • new forms of a pharmaceutically useful compound may provide an opportunity to improve the performance characteristics of pharmaceutical products.
  • discovery of additional polymorphic forms, including solvate polymorphs may help in the identification of the polymorphic content of a batch of an active pharmaceutical ingredient. For example, in some cases, different forms of the same drug can exhibit very different solubility and different dissolution rates.
  • Crystalline forms are characterized by scattering techniques, e.g., x-ray diffraction powder pattern, by spectroscopic methods, e.g., infra-red, 13 C nuclear magnetic resonance spectroscopy, and by thermal techniques, e.g., differential scanning calorimetry or differential thermal analysis.
  • the compound of this invention is best characterized by the X-ray powder diffraction pattern determined in accordance with procedures that are known in the art. For a discussion of these techniques see J. Haleblian, J. Pharm. Sci. 1975 64:1269-1288, and J. Haleblian and W. McCrone, J. Pharm. Sci. 1969 58:91 1-929.
  • the PXRD data reported herein were obtained using copper Ka radiation, and were obtained using a Bruker AXS D8 Advance Powder X-ray Diffractometer. It may be noted that one skilled in the art may easily recognize the presence or absence of the certain peaks located in an X-ray powder diffraction pattern and which are characteristic of other crystalline forms.
  • Differential scanning calorimetric analyses reported herein were carried out using a DSC Q1000 model from TA Instruments with a ramp of 10°C/minute up to 200°C. The starting temperature was 20°C and ending temperature was 200°C.
  • Thermogravimetric analysis analyses reported herein were carried out using a TGA Q500 V6.4 Build 193 from TA Instruments, with a ramp of 10°C/minute up to 200°C.
  • a diffraction angle (2 ⁇ ) in powder X-ray diffractometry may have an error in the range of ⁇ 0.2°. Therefore, the aforementioned diffraction angle values should be understood as including values in the range of about ⁇ 0.2°. Accordingly, the present invention includes not only crystals whose peak diffraction angles in powder X-ray diffractometry completely coincide with each other, but also crystals whose peak diffraction angles coincide with each other with an error of about ⁇ .0.2°.
  • the phrase "having a diffraction peak at a diffraction angle (2 ⁇ ⁇ 0.2°) of 7.9°” means “having a diffraction peak at a diffraction angle (2 ⁇ ) of 7.7° to 8.1°.
  • the intensities of peaks in the x-ray powder diffraction patterns of different batches of a compound may vary slightly, the peaks and the peak locations are characteristic for a specific polymorphic form. Alternatively, the term “about” means within an acceptable standard error of the mean, when considered by one of ordinary skill in the art.
  • the relative intensities of the PXRD peaks can vary depending on the sample preparation technique, crystal size distribution, various filters used, the sample mounting procedure, and the particular instrument employed.
  • a polymorphic form may be described by reference to patterns, spectra, or other graphical data as "substantially” shown or depicted in a figure, or by one or more data points. It will be appreciated that patterns, spectra, and other graphical data can be shifted in their positions, relative intensities, or other values due to a number of factors known to those of skill in the art. For example, in the crystallographic and powder X-ray diffraction arts, shifts in peak positions or the relative intensities of one or more peaks of a pattern can occur because of, without limitation, the equipment used, the sample preparation protocol, preferred packing and orientations, the radiation source, operator error, method and length of data collection, or the like.
  • CeliteTM is flux-calcined diatomaceous earth. CeliteTM is a registered trademark of World Minerals Inc.
  • a "halogenated hydrocarbon solvent” is an organic solvent containing a carbon bound to a halogen. "Halogenated hydrocarbon solvents” include, but are not limited to, dichloromethane, 1 ,2-dichloroethane, trichloroethylene, perchloroethylene, 1 ,1 ,1 - trichloroethane, chloroform, carbon tetrachloride, or the like.
  • the acronym MTBE is methyl tert-butyl ether. Polymorphs are different solids sharing the same molecular formula, yet having distinct physical properties when compared to other polymorphs of the same formula.
  • anti-solvent refers to a liquid that, when combined with a solution of imatinib mesylate, reduces solubility of the imatinib mesylate in the solution, causing crystallization or precipitation in some instances spontaneously, and in other instances with additional steps, such as seeding, cooling, scratching and/or concentrating.
  • a polymorphic form may be described by reference to patterns, spectra, or other graphical data as "substantially” shown or depicted in a figure, or by one or more data points. It will be appreciated that patterns, spectra, and other graphical data can be shifted in their positions, relative intensities, or other values due to a number of factors known to those of skill in the art. For example, in the crystallographic and powder X-ray diffraction arts, shifts in peak positions or the relative intensities of one or more peaks of a pattern can occur because of, without limitation, the equipment used, the sample preparation protocol, preferred packing and orientations, the radiation source, operator error, method and length of data collection, or the like.
  • crystalline Form-Y, crystalline Form-Y', and crystalline Form-Z may refer to purer forms of crystalline imatinib mesylate, they may refer to purer forms of the same polymorph of crystalline imatinib mesylate, or they may refer to different polymorphs of imatinib mesylate. They may be solvates, be mixtures of polymorphs, or have different crystal defects. All percentages and ratios used herein are by weight of the total composition and all measurements made are at about 25°C and about normal pressure, unless otherwise designated. All temperatures are in degrees Celsius unless specified otherwise.
  • EXAMPLE 1 Preparation of crystalline Form-Y of imatinib mesylate.
  • Imatinib (15 g) is suspended in methanol (150 mL) at about 25 to about 30°C and the mixture is cooled to about 0°C to -10°C. Methanesulfonic acid (1.86 mL) is added at the same temperature with stirring for about 20 minutes. Methyl tertiary- butyl ether (600 mL) is added over 10 minutes and the mixture is stirred for about 1 hour at about 0°C to 20°C. The suspension is filtered under a nitrogen atmosphere, washed with MTBE (25 mL) and suction dried for about 10 minutes to obtain a moist solid (Sample 1 ).
  • the moist solid is dried at about 45°C for about 140 hours in a vacuum tray dryer (VTD). Samples are collected at intervals such as at 30 hours (Sample 2), at 60 hours (Sample 3) and at 140 hours (Sample 4), for analysis. Yield: 8.7 g (58%).
  • EXAMPLE 2 Preparation of crystalline Form-Y of imatinib mesylate.
  • Imatinib (5 g) is suspended in methanol (50 mL) at about 25°C to about 30°C and is cooled to about 0°C to -10°C. Methanesuifonic acid (0.62 mL) is added at the same temperature and the mixture is stirred for about 20 minutes. Methyl tertiary- butyl ether (200 mL) is added over 10 minutes and the mixture is stirred for about 1 hour at about 0°C to 20°C. The suspension is filtered under a nitrogen atmosphere, washed with MTBE (8 mL) and suction dried for about 10 minutes, to obtain a moist solid. The moist solid is dried at about 45°C for about 22 hours in a vacuum tray dryer (VTD). The obtained solid is placed in a humidity chamber (conditions of humidity chamber: 40% RH at 30°C) and dried for about 22 hours, to obtain 2.91 g of the title compound. Analysis gives the following results:
  • Imatinib (10 g) and methanol (100 mL) are charged into a round bottom flask and stirred at 27°C. Cooled the suspension to about 0°C to -5°C and methanesuifonic acid (1.30 ml_) is added at the same temperature. The mixture is stirred for about 15 minutes to obtain a clear solution, filtered, and the filtrated transferred to a round bottom flask. Charged Imatinib mesylate (Form-Y) seed material (0.2 g) at about -3°C and added methyl tertiary-butyl ether (150 mL) over 30 minutes and the mixture is stirred for about 1 hour at about 0°C to -5°C.
  • the suspension is filtered under a nitrogen atmosphere, washed with MTBE (40 mL).
  • the obtained solid is dried at 45°C for about 4 hours in a vacuum tray dryer (VTD), stopped the drying and material left overnight under vacuum.
  • the obtained solid is placed in a humidity chamber (conditions of humidity chamber: 45% RH at 30°C) for about 23 hours.
  • the solid obtained is dried at about 45°C for about 4 hours in a vacuum tray dryer (VTD) to obtain 10.51 g of the title compound.
  • EXAMPLE 4 Preparation of crystalline Form-Y 1 of imatinib mesylate. Imatinib (60 g) and methanol (600 mL) are charged into a round bottom flask and stirred at 27°C. Cooled the suspension to about 0°C to -10°C and methanesulfonic acid ( 1.68 g) is added at the same temperature. The mixture is stirred for about 15 minutes to obtain a clear solution.
  • Imatinib mesylate (Form-Y) seed material (1.2 g) at about -4°C and added methyl tertiary-butyl ether (1200 mL) over 30 minutes and the mixture is stirred for about 75 minutes at about 0°C to -5°C.
  • the suspension is filtered under a nitrogen atmosphere, washed with MTBE (240 mL).
  • the obtained solid is dried at about 45°C for about 23 hours in a vacuum tray dryer (VTD).
  • the obtained solid is placed in a humidity chamber (conditions of humidity chamber: 45% RH at 30°C) for about 42 hours.
  • the solid obtained is dried at about 45°C for about 5 hours in a vacuum tray dryer (VTD) to obtain 63.89 g of the title compound.
  • Analysis gives the following results
  • Imatinib mesylate (5 g) and dimethylsulfoxide (15 ml.) are mixed at about 27°C, heated to about 90°C for dissolution, and filtered to remove any particles.
  • Dichloromethane 250 ml_ in a separate vessel is cooled to about -3°C.
  • Imatinib mesylate solution in dimethylsulfoxide is added to the precooled dichloromethane at the same temperature and stirred for 1 hour at about -3°C to about 0°C.
  • the formed solid is collected by filtration, washed with dichloromethane (10 ml_), suction dried, and finally dried at about 60°C in a vacuum tray dryer. Yield: 220 mg.
  • XRPD pattern Figure 10.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention a pour objet des formes cristallines de mésylate d'imatinib et leur procédé de préparation.
PCT/US2011/024137 2010-02-09 2011-02-09 Polymorphes de mésylate d'imatinib Ceased WO2011100282A2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
IN325CH2010 2010-02-09
IN325/CHE/2010 2010-02-09
IN1354/CHE/2010 2010-05-13
IN1354CH2010 2010-05-13
US34535110P 2010-05-17 2010-05-17
US61/345,351 2010-05-17
US36388210P 2010-07-13 2010-07-13
US61/363,882 2010-07-13

Publications (2)

Publication Number Publication Date
WO2011100282A2 true WO2011100282A2 (fr) 2011-08-18
WO2011100282A3 WO2011100282A3 (fr) 2011-12-15

Family

ID=44368404

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/024137 Ceased WO2011100282A2 (fr) 2010-02-09 2011-02-09 Polymorphes de mésylate d'imatinib

Country Status (1)

Country Link
WO (1) WO2011100282A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2604596A1 (fr) * 2011-12-16 2013-06-19 Deva Holding Anonim Sirketi Polymorphes d'imatinib
US11229650B2 (en) 2019-05-16 2022-01-25 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
US11980689B2 (en) 2013-07-31 2024-05-14 Avalyn Pharma Inc. Inhaled imatinib for treatment of pulmonary arterial hypertension (PAH)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7300938B2 (en) * 2003-06-02 2007-11-27 Hetero Drugs Limited Polymorphs of imatinib mesylate
UA84462C2 (ru) * 2004-04-02 2008-10-27 Институт Фармацевтични Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
KR101348625B1 (ko) * 2004-09-02 2014-01-07 씨아이피엘에이 엘티디. 이매티닙 메실레이트의 안정한 결정형 및 그의 제조방법

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2604596A1 (fr) * 2011-12-16 2013-06-19 Deva Holding Anonim Sirketi Polymorphes d'imatinib
US11980689B2 (en) 2013-07-31 2024-05-14 Avalyn Pharma Inc. Inhaled imatinib for treatment of pulmonary arterial hypertension (PAH)
US11229650B2 (en) 2019-05-16 2022-01-25 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
US11298355B2 (en) 2019-05-16 2022-04-12 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
US11413289B2 (en) 2019-05-16 2022-08-16 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
US11806349B2 (en) 2019-05-16 2023-11-07 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
US11813263B2 (en) 2019-05-16 2023-11-14 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof

Also Published As

Publication number Publication date
WO2011100282A3 (fr) 2011-12-15

Similar Documents

Publication Publication Date Title
KR101470715B1 (ko) 다사티닙 다결정체 및 그의 제조방법과 약물 조성물
US7655798B2 (en) Process of making crystalline Type II aripiprazole
JP4414237B2 (ja) ケチアピンヘミフマレートの結晶形
US11168057B2 (en) Polymorphs and co-crystals of roxadustat
WO2015145415A2 (fr) Formes solides d'ibrutinib et leur procédé de production
CZ2015504A3 (cs) Krystalické formy obeticholové kyseliny
CA2793413A1 (fr) Forme cristalline d'edoxaban tosylate monohydrate et son procede de fabrication
WO2010139980A1 (fr) Procédé de préparation d'un monohydrate de dasatinib cristallin
SG185594A1 (en) A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
WO2010056384A1 (fr) Solvates de lénalidomide et procédés correspondants
WO2007109799A2 (fr) Polymorphes de malate d'eszopiclone
WO2010129636A2 (fr) Lénalidomide polymorphe
WO2013132511A1 (fr) Nouveau polymorphe de chlorhydrate de lurasidone
WO2011100282A2 (fr) Polymorphes de mésylate d'imatinib
WO2017037608A1 (fr) Formes solides de ténofovir alafénamide et sels associés, procédés pour leur préparation et compositions pharmaceutiques associées
WO2011080651A2 (fr) Formes polymorphes de fébuxostat
EP2688649B1 (fr) Forme polymorphe de lénalidomide
JP2022525125A (ja) ブレイアコニチンａのｅ結晶形及びその製造方法と応用
WO2014128728A2 (fr) Formes solides de cabazitaxel et leurs procédés de préparation
WO2014195977A2 (fr) Nouveaux polymorphes de vismodegib
WO2016157136A1 (fr) Formes cristallines de l'idélalisib
CA2600541C (fr) Procede de fabrication d'un aripiprazole type ii cristallin
CN116199668B (zh) Evobrutinib化合物盐型及其制备方法
EA030029B1 (ru) СТАБИЛЬНЫЙ ПОЛИМОРФ СОЛИ (2R)-4-ОКСО-4-[3-(ТРИФТОРМЕТИЛ)-5,6-ДИГИДРО[1,2,4]ТРИАЗОЛО[4,3-α]ПИРАЗИН-7(8H)-ИЛ]-1-(2,4,5-ТРИФТОРФЕНИЛ)БУТАН-2-АМИНА И L-ВИННОЙ КИСЛОТЫ
CN113840605A (zh) N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺及其盐的结晶和无定形形式，及其制备方法和治疗用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11742711

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11742711

Country of ref document: EP

Kind code of ref document: A2